Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesProprietary Laboratory AnalysesCPT cpt-0029u-focused-pharmacogenomics-panel-mayo-clinic
    Ask Trek AI about this page

    CPT 0029U: Focused Pharmacogenomics Panel (Mayo Clinic)

    CPT code 0029U is a Proprietary Laboratory Analyses (PLA) code that describes the Mayo Clinic Focused Pharmacogenomics Panel, a targeted pharmacogenomic test that analyzes specific genetic variants to inform medication selection and dosing; the service is a laboratory-based genetic testing panel typically performed in a clinical laboratory or reference lab setting and ordered by clinicians managing pharmacotherapy.

    For related coverage guidance, see recent payer policy updates: RTM Testing of Homocysteine Metabolism-Related Conditions, Multimarker Serum Testing Related to Ovarian Cancer, Genomic Profiling for Selecting Targeted Cancer Therapies.

    Customize your policy alerts

    Sign up for cpt 0029U policy alerts

    Get alerted when payer policies referencing 0029U are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A 58-year-old patient with a history of multiple chronic conditions, including major depressive disorder and atrial fibrillation, is evaluated by a primary care physician and a clinical pharmacist for medication optimization after a recent adverse drug reaction. The clinician orders the Mayo Clinic Focused Pharmacogenomics Panel (0029U) to identify clinically relevant germline variants in pharmacokinetic and pharmacodynamic genes that influence response to commonly prescribed psychiatric and cardiovascular medications. Blood is drawn in an outpatient clinic or at a hospital ambulatory lab; the specimen is sent to the Mayo Clinic laboratory for analysis. Results are returned as a targeted report indicating variant alleles and recommended medication gene interactions to inform prescribing decisions. The typical workflow includes pre-test counseling, specimen collection (venipuncture), laboratory processing and bioinformatic analysis, result reporting to the ordering provider, and a follow-up visit or medication adjustment by the prescriber or clinical pharmacist.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    81002Urinalysis, by dip stick or tablet reagent; non-automated, without microscopyData not available in the input.
    36415Collection of venous blood by venipunctureCommonly performed immediately before 0029U to obtain the specimen for pharmacogenomic testing.
    88360Immunohistochemistry, per single antigen; initial antibody stainData not available in the input.
    80400Drug assay, qualitative; multiple drug classesData not available in the input.
    0000UProprietary Laboratory Analyses (example PLA)Data not available in the input.

    Related Modifiers

    5 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    99Modifier 99 is a placeholder modifier used when more modifiers apply to a single procedure than the claim form or electronic field allows. The AMA classifies it under Provider Services and Ambulatory…- Use CPT modifier -99 when more modifiers apply to a single procedure line than the claim form or payer field allows (CMS/Noridian: when more than four modifiers are needed); append modifier 99 on…
    3PThe CPT Category II modifier -3P denotes a performance‑measure exclusion when a required quality action was not performed because of system‑level constraints. It is appended only to Category II…- When to apply: Use CPT Category II modifier 3P only with Category II (‘‘F’’) codes when a specific quality measure’s specifications allow a system‑level exclusion — append 3P to indicate the…

    Related Provider Taxonomies

    8 rows

    Taxonomy CodeSpecialtyNotes
    208000000XPediatrics PhysicianA pediatrician is concerned with the physical, emotional and social health of children from birth to young adulthood. Care encompasses a broad spectru…
    207Q00000XFamily Medicine PhysicianFamily Medicine is the medical specialty which is concerned with the total health care of the individual and the family. It is the specialty in breadt…
    2084P0800XPsychiatry PhysicianA Psychiatrist specializes in the prevention, diagnosis, and treatment of mental disorders, emotional disorders, psychotic disorders, mood disorders, …
    2278P3900XNeonatal/Pediatric Certified Respiratory TherapistThe care and treatment of premature infants, newborns and children. This includes management of mechanical ventilation, assessment, diagnostics and g…
    103GC0700XDeactivated - Clinical Neuropsychologist
    2471C3401XComputed Tomography Radiologic TechnologistA radiologic technologist who specializes in computed tomography (CT) and is appropriately educated and trained, consistent with nationally recognized…
    2279P3900XNeonatal/Pediatric Registered Respiratory TherapistThe care and treatment of premature infants, newborns and children. This includes management of mechanical ventilation, assessment, diagnostics and g…
    207NI0002XClinical & Laboratory Dermatological Immunology PhysicianA dermatologist who utilizes various specialized laboratory procedures to diagnose disorders characterized by defective responses of the body's immune…

    Related ICD-10-CM Codes

    28 rows

    ICD-10-CM CodeDescription
    C50.919Malignant neoplasm of unspecified site of unspecified female breast
    E03.9Hypothyroidism, unspecified
    E11.9Type 2 diabetes mellitus without complications
    E78.5Hyperlipidemia, unspecified
    F10.20Alcohol dependence, uncomplicated
    F11.20Opioid dependence, uncomplicated
    F32.9Major depressive disorder, single episode, unspecified
    F33.1Major depressive disorder, recurrent, moderate
    F41.1Generalized anxiety disorder
    G43.909Migraine, unspecified, not intractable, without status migrainosus

    Showing 1–10 of 28

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    RTM Testing of Homocysteine Metabolism-Related ConditionsOscar Health2026-10-01
    Multimarker Serum Testing Related to Ovarian CancerBlue Cross Blue Shield - Rhode Island2026-09-01
    Genomic Profiling for Selecting Targeted Cancer TherapiesBlue Cross Blue Shield - Rhode Island2026-09-01
    Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic DisordersBlue Cross Blue Shield - Rhode Island2026-09-01
    Biomarker and Genetic/Molecular Testing Coverage and Prior AuthorizationBlue Cross Blue Shield - Rhode Island2026-09-01
    Non-Invasive Prenatal Testing (NIPT)univerahealthcare2026-08-17
    Lumizyme (alglucosidase alfa) — Pompe Disease (acid alpha‑glucosidase deficiency)Cigna2026-08-15
    Molecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment DecisionsColorado Rocky Mountain Health Plans2026-08-01
    Carrier Testing Panels for Genetic DiseasesColorado Rocky Mountain Health Plans2026-08-01
    Molecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment DecisionsColorado Rocky Mountain Health Plans2026-08-01

    Related Codes

    CPT-0001U-PRECISETYPE-HEA-MULTIPLEX-RBC-ANTIGEN-GENOTYPING

    CPT 0001U: PreciseType HEA Erythrocyte Antigen Genotyping

    CPT-0002U-POLYPDX-URINE-METABOLOMIC-ASSAY-ADENOMATOUS-POLYP-RISK

    CPT 0002U: PolypDX™ Urine Metabolomic Risk Assay

    CPT-0003U-OVAR-A-NEXT-GENERATION-OVARIAN-CANCER-RISK-ASSAY

    CPT 0003U: Overa (MIA2G) Ovarian Cancer Risk Assay

    CPT-0005U-PROSTATE-EXOSOMEDX-INTELLISCORE-GENE-EXPRESSION-URINE-TEST

    CPT 0005U: ExosomeDx Prostate (IntelliScore) urine gene expression test

    CPT-0007U-TOXPROTECT-URINE-DRUG-SCREEN-WITH-DNA-AUTHENTICATION

    CPT 0007U: ToxProtect Urine Drug Screen With DNA Authentication

    CPT-0008U-H-PYLORI-ANTIBIOTIC-RESISTANCE-SEQUENCING-PANEL

    CPT 0008U: H. pylori Antibiotic Resistance Gene Panel

    CPT-0009U-DEPARRAY-HER2-FISH-TUMOR-CELL-ISOLATION

    CPT 0009U: DEPArray HER2 Tumor‑Cell Isolation with FISH Analysis

    CPT-0010U-BACTERIAL-TYPING-WHOLE-GENOME-SEQUENCING-MAYO-CLINIC

    CPT 0010U: Bacterial Typing by Whole Genome Sequencing, Mayo Clinic

    CPT-0011U-CORDANT-CORE-ALGORITHMIC-ORAL-FLUID-DRUG-TEST

    CPT 0011U: Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

    CPT-0016U-BCR-ABL1-MAJOR-MINOR-FUSION-TRANSCRIPT-TESTING

    CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcripts

    Showing 1–10 of 536

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.